Phase III study comparing triplet chemotherapy with S-1 and cisplatin plus docetaxel versus doublet chemotherapy with S-1 and cisplatin for advanced gastric cancer (JCOG1013).

作者
Yasuhide Yamada,Narikazu Boku,Junki Mizusawa,Satoru Iwasa,Shigenori Kadowaki,Norisuke Nakayama,Mizutomo Azuma,Takeshi Sakamoto,Kohei Shitara,Tatsuya Okuno,Keisho Chìn,Akira Nozaki,Masaki Nakamura,Hiroki Hara,Hiroshi G. Katayama,Haruhiko Fukuda,Takaki Yoshikawa,Takeshi Sano,Mitsuru Sasako,Masanori Terashima
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:36 (15_suppl): 4009-4009 被引量:15
标识
DOI:10.1200/jco.2018.36.15_suppl.4009
摘要

4009 Background: Doublet chemotherapy with S-1 and cisplatin (CS) is one of the standard first-line chemotherapy for advanced gastric cancer in Japan. Triplet chemotherapy with docetaxel added to CS (DCS) showed a promising activity associated with feasible toxicities in a phase II study. We conducted a phase III study, JCOG1013, to investigate whether DCS improved overall survival (OS) compared with CS. Methods: Patients with previously untreated, human epidermal growth factor receptor 2 negative or unknown, unresectable or recurrent gastric adenocarcinoma, performance status 0 to 1, and adequate organ function were eligible. They were randomly 1:1 assigned to receive CS (S-1 40-60 mg orally twice a day for 3 weeks, cisplatin 60 mg/m2 on day 8, repeated every 5 weeks), or DCS (docetaxel 40 mg/m2, cisplatin 60 mg/m2 on day 1, S-1 40-60 mg orally twice a day for 2 weeks, repeated every 4 weeks). The primary endpoint was OS. A total of 740 patients were required to detect an increase in median OS from 13.5 months in the CS arm to 16.5 months in the DCS arm, corresponding to a hazard ratio (HR) of 0.8435, with a one-sided alpha of 5% and power of 80%. Results: From Apr 2012 to Mar 2016, 741 patients were enrolled in total (CS 371, DCS 370). Median OS was 14.2 and 15.3 months for DCS and CS, respectively (HR 0.99; 95% confidence interval [CI] 0.85-1.16; one-sided stratified log-rank p = 0.47). By histological subtypes, median OS was 13.3 months for DCS and 14.2 months for CS (p = 0.83) in the diffuse type (n = 482), and 17.5 months for both DCS and CS (p = 0.65) in the intestinal type (n = 259). Median progression-free survival was 7.4 months for DCS and 6.5 months for CS (HR 0.99; 95% CI, 0.86-1.15; p = 0.92). The overall response rate was 59.3% for DCS and 56.0% for CS (p = 0.50). The most common adverse events of grade 3 or 4 were neutropenia (DCS 58.5%, CS 32.1%), febrile neutropenia (DCS 7.6%, CS 5.7%), and diarrhea (DCS 7.0%, CS 7.4%). Conclusions: Addition of docetaxel to CS failed to improve OS of patients with untreated advanced gastric cancer. Therefore, CS remains the standard treatment for first-line chemotherapy for advanced gastric cancer. Clinical trial information: UMIN000007652.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
四十发布了新的文献求助10
刚刚
共享精神的应助被lily采纳,获得10
2秒前
2秒前
Li发布了新的文献求助10
2秒前
3秒前
aqqq完成签到,获得积分10
3秒前
lawang发布了新的文献求助10
3秒前
慕青的应助被要减肥含灵采纳,获得10
3秒前
所所的应助被leslieyw采纳,获得30
4秒前
终梦完成签到,获得积分0
5秒前
5秒前
5秒前
李健的应助被小王子采纳,获得10
6秒前
李琦发布了新的文献求助10
6秒前
小SCI完成签到,获得积分10
6秒前
7秒前
tata完成签到 ,获得积分10
7秒前
七听的应助被羽化成仙采纳,获得200
9秒前
纪言七许发布了新的文献求助10
9秒前
小徐同志完成签到,获得积分10
9秒前
9秒前
脑洞疼的应助被yansiyi采纳,获得10
10秒前
xue完成签到,获得积分10
10秒前
10秒前
撒上大声说完成签到,获得积分10
11秒前
小SCI发布了新的文献求助10
11秒前
1111完成签到,获得积分10
11秒前
花生油炒花生米完成签到 ,获得积分10
12秒前
郭玉完成签到,获得积分10
12秒前
田様的应助被合适的安梦采纳,获得10
12秒前
13秒前
14秒前
14秒前
yzk完成签到,获得积分10
14秒前
15秒前
xue发布了新的文献求助10
16秒前
16秒前
16秒前
lingmzzy完成签到,获得积分10
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187362
求助须知:如何正确求助?哪些是违规求助? 9575478
关于积分的说明 21841431
捐赠科研通 7785067
什么是DOI,文献DOI怎么找? 3434943
关于科研通互助平台的介绍 2559401
邀请新用户注册赠送积分活动 2481820